Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.62 |
| ▸ | JAK3 | P52333 | 6/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691216 | 0.85 | JAK2 (0.68) | JAK2JAK3PTK2NUDT1JAK1 | |
| SCHEMBL18615217 | 0.84 | JAK2 (0.58) | JAK2JAK3NUDT1ADORA2AADORA1 | |
| SCHEMBL18225402 | 0.80 | JAK2 (0.46) | JAK2JAK3PTK2TGFBR2ADORA2A | |
| SCHEMBL12517030 | 0.80 | JAK2 (0.63) | JAK2JAK3PTK2NUDT1ADORA2A | |
| SCHEMBL3265099 | 0.80 | JAK2 (0.68) | JAK2JAK3NUDT1TGFBR2JAK1 | |
| SCHEMBL2271514 | 0.79 | JAK2 (0.62) | JAK2JAK3PTK2NUDT1JAK1 | |
| SCHEMBL2277264 | 0.79 | JAK2 (0.62) | JAK2JAK3PTK2NUDT1KDM4E | |
| SCHEMBL18367046 | 0.78 | JAK2 (0.77) | JAK2JAK3PTK2NUDT1ALDH1A3 | |
| SCHEMBL3227238 | 0.78 | JAK2 (0.70) | JAK2JAK3PTK2 | |
| SCHEMBL5777168 | 0.78 | KDM4E (0.49) | TGFBR2ADORA2AADORA1TDO2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9434732-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9145399-B2 | Substituted bicyclic triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145399-B2 | Substituted bicyclic triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8609687-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011086098-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2288260-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| WO-2009155551-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155551-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 312/4885 |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885PTK2 386/4885 |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 312/4885 |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 312/4885 |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | JAK2 4105/4885JAK3 3487/4885PTK2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.